Our passion for immuno-oncology is relentless

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology products to improve the lives of patients with cancer.

With more than 15 years of experience researching and developing exciting new therapies, our dedication to science has brought us to the forefront in immuno-oncology, where we are poised to change the approach to cancer treatment.

Our mission is to fundamentally change the way cancer is treated to improve the lives of patients

Our vision is to develop and seek approval for multiple product candidates for patients with different cancers. These product candidates have the potential to combine with and enhance current standard-of-care or other emerging immuno-oncology therapies to achieve the best possible outcomes.

NewLink Genetics: Born to beat the odds

1990s Dr Link and Dr Vahanian team up to pursue immuno-oncology as the future of cancer treatment
1999 NewLink Genetics is founded
2010 Expansion of the clinical trials program leads to the first pancreatic cancer patient enrolled in the IMPRESS trial
2016 Continuing significant progress in the clinical development of IDO pathways

IDO=indoleamine 2,3-dioxygenase.


Dr Charles Link


Up until [2013], I continued to practice medicine, which is unusual for a biotech CEO, I realize, but I’ve always felt very committed to understanding what patients are going through in real time.